Paper
2022.10.14
Publication of a clinical phase 2 study of SCO-792
Paper
2022.06.17
Publication of medicinal chemistry research on SCO-792, an enteropeptidase inhibitor
Paper
2021.08.19
Publication of a preclinical study: Inositol hexakisphosphate kinase (IP6K) is crucial in regulating plasma phosphate levels in vivo, and SCO-006-mediated IP6K inhibition is a potential novel treatment strategy against hyperphosphatemia
Paper
2021.07.29
Publication of a clinical phase 1 study: SCO-267, a GPR40 full agonist, is safe and well-tolerated, exhibits good potential for once-daily dosing, and improves glycemic control in humans
Paper
2021.02.08
Publication of a preclinical study: chronic exposure to SCO-267, a GPR40, is effective in treating diabetes in preclinical models
Paper
2020.12.23
Publication of a preclinical study: the enteropeptidase inhibitor SCO-792 is therapeutically effective for improving renal function in a nondiabetic rat model of chronic kidney disease
Paper
2020.12.07
Publication of a preclinical study: SCO-792, an enteropeptidase inhibitor, improves obesity via microbiota-driven mechanisms in mice
Page Top